Kerry J. Rodabaugh, Rebecca Anderson
Background: Patients with advanced or recurrent endometrial cancer have limited options once the disease progresses following chemotherapy. The combination of checkpoint inhibitors and tyrosine kinase inhibitors has recently been approved but has the potential for significant morbidity.
Case Report: We report a case of a patient who developed necrotizing fasciitis while receiving pembrolizumab and lenvatinib as therapy for metastatic uterine carcinosarcoma. Management required four separate surgeries and prolonged hospitalization.
Conclusion: A literature review found no previous reports of this complication with endometrial carcinomas. The purpose of this report is to raise awareness of the possibility of necrotizing fasciitis in relation to these drugs.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi